Fisetin Fights Periodontitis by Shielding Fibroblasts from Oxidative Stress
A multiomics and network pharmacology study reveals fisetin reduces alveolar bone loss and protects periodontal fibroblasts from oxidative damage.
Summary
Researchers used network pharmacology, single-cell transcriptomics, spatial transcriptomics, and in vitro experiments to investigate how fisetin — a plant-derived flavonoid — treats periodontitis. They identified 81 shared targets between fisetin and periodontitis disease genes, with oxidative stress pathways prominently enriched. In a rat ligation model, fisetin at 20 and 100 mg/kg significantly reduced alveolar bone destruction. Single-cell RNA sequencing pinpointed fibroblasts as the primary cell population affected by fisetin, and spatial transcriptomics confirmed their localization in diseased tissue. In vitro, fisetin reduced ROS levels, restored antioxidant enzyme expression, and improved proliferation and reduced apoptosis in hydrogen peroxide-stressed human periodontal ligament fibroblasts. These findings position fisetin as a promising pharmacological adjunct to conventional periodontal therapy.
Detailed Summary
Periodontitis affects nearly half of adults worldwide and causes irreversible destruction of tooth-supporting tissues including the gingiva, periodontal ligament, and alveolar bone. Standard mechanical debridement often fails in complex cases, and lost tissue cannot be regenerated, making new pharmacological strategies urgently needed. Oxidative stress — driven by excessive reactive oxygen species (ROS) released during immune responses to periodontal pathogens — is a central driver of tissue damage, making antioxidant compounds attractive therapeutic candidates.
Fisetin, a flavonoid polyphenol found in fruits and vegetables, ranks highest in antioxidant efficiency among ten tested flavonoids. This study systematically investigated its mechanisms in periodontitis using a layered multiomics and network pharmacology approach. By cross-referencing fisetin's predicted drug targets (from SwissTargetPrediction and ChemMapper) against periodontitis disease targets (from GeneCards, OMIM, and DisGeNET), the researchers identified 81 shared therapeutic targets. GO and KEGG enrichment analyses highlighted oxidative stress regulation, PI3K/Akt, NF-κB, and Wnt/β-catenin signaling as key pathways. Molecular docking confirmed stable binding of fisetin to top-ranked target proteins from two PPI network modules (MCODE_1 and MCODE_2), with favorable binding energies.
In a rat ligation model of periodontitis, oral gavage of fisetin at both 20 mg/kg and 100 mg/kg every two days for six weeks significantly reduced alveolar bone loss compared to untreated controls, as confirmed by micro-CT imaging. Single-cell RNA sequencing of nine datasets (32,984 cells total, from GSE171213) with Harmony batch correction and UMAP visualization revealed that fibroblast populations showed the most pronounced transcriptional changes in periodontitis and were the primary cellular targets of fisetin's drug targets, as quantified by the AUCell algorithm. pySCENIC transcription factor network analysis further identified key regulons governing fibroblast state transitions between healthy and diseased conditions. Spatial transcriptomics data (GSE206621) using RCTD deconvolution confirmed that fibroblasts are spatially enriched in periodontitis-affected gingival tissue, corroborating the single-cell findings.
In vitro validation used human periodontal ligament fibroblasts (PDLFs) stressed with 200 μM H₂O₂ — a concentration reducing viability to ~70% of controls. Fisetin treatment at 15 and 30 μM following H₂O₂ exposure significantly reduced intracellular ROS (measured by DCFH-DA probe), restored expression of key antioxidant enzymes (assessed by Western blot), improved cell proliferation (EdU assay), and reduced apoptosis (Annexin V-FITC/PI assay) in a dose-responsive manner.
Collectively, these findings establish that fisetin combats periodontitis primarily by reducing oxidative stress in fibroblast populations, protecting periodontal ligament integrity and limiting bone destruction. The study provides a mechanistic rationale for clinical trials evaluating fisetin as an adjunct to conventional periodontal therapy, potentially improving outcomes for patients with refractory disease.
Key Findings
- 81 shared targets identified between fisetin and periodontitis, with oxidative stress pathways prominently enriched.
- Fisetin at 20 and 100 mg/kg significantly reduced alveolar bone destruction in a rat ligation periodontitis model.
- Single-cell transcriptomics identified fibroblasts as the primary cell population targeted by fisetin in periodontitis.
- Spatial transcriptomics confirmed fibroblast enrichment in diseased gingival tissue, validating single-cell findings.
- Fisetin reduced ROS, restored antioxidant enzymes, improved proliferation, and decreased apoptosis in stressed PDLFs in vitro.
Methodology
The study combined network pharmacology (81 shared fisetin-PD targets), molecular docking, a rat ligation periodontitis model (n=8/group, 6 weeks), single-cell RNA-seq integration of 9 datasets (32,984 cells, Harmony/UMAP), spatial transcriptomics deconvolution (RCTD), and in vitro H₂O₂-stressed human PDLF experiments with ROS, Western blot, EdU, and Annexin V assays.
Study Limitations
The rat ligation model does not fully replicate the polymicrobial complexity of human periodontitis, and the study lacks long-term safety or pharmacokinetic data for fisetin in humans. The in vitro H₂O₂ model is a simplified oxidative stress surrogate, and clinical translation requires randomized controlled trials to confirm efficacy and optimal dosing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.